Neuroprotection With N-acetyl Cysteine for Patients With Progressive Multiple Sclerosis (NACPMS)
Randomized Controlled Trial of N-acetyl Cysteine as a Neuroprotective Agent in Progressive Multiple Sclerosis
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Contact
Study Contact
- Name: Uk Sok Shin, BA
- Phone Number: (415) 321-9373
- Email: uksok.shin@ucsf.edu
Study Contact Backup
- Name: Emmanuelle Waubant, MD, PhD
- Phone Number: 415-514-8199
- Email: emmanuelle.waubant@ucsf.edu
Study Locations
-
-
California
-
San Francisco, California, United States, 94158
- University of California, San Francisco
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- - 40-70 (inclusive) years in age,
- meet 2017 McDonald criteria (Thompson 2018),
- patients with primary or secondary progressive MS (Thompson 2018),
- at least 2 years since progressive symptom onset,
- evidence of clinical changes over the previous 2 years unrelated to relapses: increased EDSS or 20% slowing on 25-foot walk, change of ambulatory support, cognitive change documented on cognitive testing. Progression defined by patients in terms of ambulation perimeter or type of support to ambulate are acceptable if aforementioned physician-based measure changes are not available.
- EDSS score 3.0 to 7.0 (inclusive),
- can be on a stable disease-modifying treatment initiated > 3 months prior to screening,
- can be on stable doses of dalfampridine initiated at least one month before screening.
Exclusion Criteria:
- - MS relapses in the previous 6 months
- oral glucocorticosteroid treatment within the prior 3 months
- patient with issues undergoing MRI scans
- pregnancy or breastfeeding
- women of child-bearing potential not able to utilize an effective form of contraception for the duration of the study
- history of bleeding disorders
- active gastrointestinal ulcers
- abnormal liver function testing (aminotransferase (AST) or alanine aminotransferase (ALT) >2 times upper limit of normal)
- current treatment for active malignancy or metastatic malignancy treated in the past year
- alcohol or substance use disorder
- allergy to NAC
- planned surgery or move within 15 months
- use of medications/supplements with antioxidant properties (including over-the-counter NAC)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: N-acetyl cysteine
N-acetyl cysteine (NAC) 1200mg t.i.d.
|
N-acetyl cysteine (NAC) is a Glutathione (GSH) precursor with antioxidant properties which make it relevant for neuroprotection.
Other Names:
|
|
Placebo Comparator: Placebo
Placebo 1200mg t.i.d.
|
Lactose Monohydrate, USP (100%), magnesium stearate, silicon dioxide NF
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Safety and tolerability
Time Frame: 15 months
|
Number of adverse events recorded by system, severity, and by relationship to treatment arm.
|
15 months
|
|
Effect of NAC on on progression of brain, thalamic and cervical cord atrophy
Time Frame: 15 months
|
The primary endpoint is brain, thalamic and cord atrophy measured by brain and cervical spine MRI at month 3 and month 15.
|
15 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Clinical effects of NAC
Time Frame: 15 months
|
Clinical effects in MS as measured by the 9-HPT, 25-foot walk, symbol digit modalities test (SDMT).
|
15 months
|
Other Outcome Measures
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Effect of NAC on progression of MS
Time Frame: 15 months
|
Monitoring progression using imaging metrics and changes captured by a wearable multi-sensor device.
|
15 months
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Nervous System Diseases
- Pathologic Processes
- Chronic Disease
- Disease Attributes
- Autoimmune Diseases
- Immune System Diseases
- Demyelinating Autoimmune Diseases, CNS
- Autoimmune Diseases of the Nervous System
- Demyelinating Diseases
- Pathological Conditions, Signs and Symptoms
- Multiple Sclerosis
- Multiple Sclerosis, Chronic Progressive
- Amino Acids, Peptides, and Proteins
- Sulfur Compounds
- Organic Chemicals
- Amino Acids
- Cysteine
- Amino Acids, Sulfur
- Acetylcysteine
Other Study ID Numbers
Other Study ID Numbers
- P0549747
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.